BioCentriq, the New Jersey Innovation Institute’s cell and gene therapy development and manufacturing center, said it completed the construction of a state-of-the-art, Good Manufacturing Practices-ready clinical manufacturing facility in South Brunswick.
Located at 7 Deer Park Drive, the 9,000-square-foot facility is adjacent to its existing pilot plant and includes all the supporting infrastructure and lab space to support the clinical manufacturing of allogeneic and autologous cell therapies and gene therapies.
“This expansion of our clinical production capacity allows us to meet the demands of our clients,” stated Haro Hartounian, senior vice president and general manager of BioCentriq. “We understand the myriad of challenges our clients face when they are optimizing and scaling up their processes to prepare for clinical manufacturing. Our team’s cumulative expertise in process development and GMP manufacturing enables us to meet the growing demand in this space.”
Initial projects will get underway in the early third quarter after validation and commissioning of the facility.